Clinical Characteristics of Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease According to Their Epitopes

Overview

Journal Front Neurol

Specialty Neurology

Date 2023 Jul 12

PMID 37435160

Authors

Jin Myoung Seok

Mi Young Jeon

Yeon Hak Chung

Hyunjin Ju

Hye Lim Lee

Soonwook Kwon

Ju-Hong Min

Eun-Suk Kang

Byoung Joon Kim

Affiliations

Soon will be listed here.

Abstract

Background: The detection of myelin oligodendrocyte glycoprotein autoantibodies (MOG-Ab) is essential for the diagnosis of MOG-Ab-associated disease (MOGAD). The clinical implications of different epitopes recognized by MOG-Ab are largely unknown. In this study, we established an in-house cell-based immunoassay for detecting MOG-Ab epitopes and examined the clinical characteristics of patients with MOG-Ab according to their epitopes.

Methods: We conducted a retrospective review of patients with MOG-Ab-associated disease (MOGAD) in our single center registry, and collected serum samples from enrolled patients. Human MOG variants were generated to detect epitopes recognized by MOG-Ab. The differences in clinical characteristics according to the presence of reactivity to MOG Proline42 (P42) were evaluated.

Results: Fifty five patients with MOGAD were enrolled. Optic neuritis was the most common presenting syndrome. The P42 position of MOG was a major epitope of MOG-Ab. The patients with a monophasic clinical course and childhood-onset patients were only observed in the group that showed reactivity to the P42 epitope.

Conclusion: We developed an in-house cell-based immunoassay to analyze the epitopes of MOG-Ab. The P42 position of MOG is the primary target of MOG-Ab in Korean patients with MOGAD. Further studies are needed to determine the predictive value of MOG-Ab and its epitopes.

Citing Articles

The MOG antibody non-P42 epitope is predictive of a relapsing course in MOG antibody-associated disease.

Liyanage G, Trewin B, Lopez J, Andersen J, Tea F, Merheb V J Neurol Neurosurg Psychiatry. 2024; 95(6):544-553.

PMID: 38290838 PMC: 11103329. DOI: 10.1136/jnnp-2023-332851.

References

Breithaupt C, Schafer B, Pellkofer H, Huber R, Linington C, Jacob U . Demyelinating myelin oligodendrocyte glycoprotein-specific autoantibody response is focused on one dominant conformational epitope region in rodents. J Immunol. 2008; 181(2):1255-63. DOI: 10.4049/jimmunol.181.2.1255. View

Lui A, Chong J, Flanagan E, Abrams A, Krysko K, Arikan B . High titers of myelin oligodendrocyte glycoprotein antibody are only observed close to clinical events in pediatrics. Mult Scler Relat Disord. 2021; 56:103253. PMC: 8678350. DOI: 10.1016/j.msard.2021.103253. View

Jurynczyk M, Messina S, Woodhall M, Raza N, Everett R, Roca-Fernandez A . Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain. 2017; 140(12):3128-3138. DOI: 10.1093/brain/awx276. View

Hamid S, Whittam D, Mutch K, Linaker S, Solomon T, Das K . What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients. J Neurol. 2017; 264(10):2088-2094. PMC: 5617862. DOI: 10.1007/s00415-017-8596-7. View

Winklmeier S, Schluter M, Spadaro M, Thaler F, Vural A, Gerhards R . Identification of circulating MOG-specific B cells in patients with MOG antibodies. Neurol Neuroimmunol Neuroinflamm. 2019; 6(6):625. PMC: 6857907. DOI: 10.1212/NXI.0000000000000625. View

Longbrake E . Myelin Oligodendrocyte Glycoprotein-Associated Disorders. Continuum (Minneap Minn). 2022; 28(4):1171-1193. PMC: 9523511. DOI: 10.1212/CON.0000000000001127. View

Hoftberger R, Sepulveda M, Armangue T, Blanco Y, Rostasy K, Cobo Calvo A . Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Mult Scler. 2014; 21(7):866-874. PMC: 4824843. DOI: 10.1177/1352458514555785. View

Reindl M, Di Pauli F, Rostasy K, Berger T . The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol. 2013; 9(8):455-61. DOI: 10.1038/nrneurol.2013.118. View

de Mol C, Wong Y, van Pelt E, Wokke B, Siepman T, Neuteboom R . The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults. Mult Scler. 2019; 26(7):806-814. PMC: 7294530. DOI: 10.1177/1352458519845112. View

10.

Jarius S, Paul F, Aktas O, Asgari N, Dale R, De Seze J . MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation. 2018; 15(1):134. PMC: 5932838. DOI: 10.1186/s12974-018-1144-2. View

11.

Akaishi T, Takahashi T, Misu T, Kaneko K, Takai Y, Nishiyama S . Difference in the Source of Anti-AQP4-IgG and Anti-MOG-IgG Antibodies in CSF in Patients With Neuromyelitis Optica Spectrum Disorder. Neurology. 2021; 97(1):e1-e12. PMC: 8312856. DOI: 10.1212/WNL.0000000000012175. View

12.

Grant-Peters M, Dos Passos G, Yeung H, Jacob A, Huda S, Leite M . No strong HLA association with MOG antibody disease in the UK population. Ann Clin Transl Neurol. 2021; 8(7):1502-1507. PMC: 8283171. DOI: 10.1002/acn3.51378. View

13.

Cobo-Calvo A, Ruiz A, Rollot F, Arrambide G, Deschamps R, Maillart E . Clinical Features and Risk of Relapse in Children and Adults with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. Ann Neurol. 2020; 89(1):30-41. DOI: 10.1002/ana.25909. View

14.

Lee H, Kim B, Waters P, Woodhall M, Irani S, Ahn S . Chronic relapsing inflammatory optic neuropathy (CRION): a manifestation of myelin oligodendrocyte glycoprotein antibodies. J Neuroinflammation. 2018; 15(1):302. PMC: 6208174. DOI: 10.1186/s12974-018-1335-x. View

15.

Waters P, Woodhall M, OConnor K, Reindl M, Lang B, Sato D . MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. Neurol Neuroimmunol Neuroinflamm. 2015; 2(3):e89. PMC: 4370386. DOI: 10.1212/NXI.0000000000000089. View

16.

Tea F, Lopez J, Ramanathan S, Merheb V, Lee F, Zou A . Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination. Acta Neuropathol Commun. 2019; 7(1):145. PMC: 6724269. DOI: 10.1186/s40478-019-0786-3. View

17.

Cobo-Calvo A, Sepulveda M, dIndy H, Armangue T, Ruiz A, Maillart E . Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults. J Neurol. 2019; 266(4):806-815. DOI: 10.1007/s00415-018-9160-9. View

18.

Wendel E, Thonke H, Bertolini A, Baumann M, Blaschek A, Merkenschlager A . Temporal Dynamics of MOG Antibodies in Children With Acquired Demyelinating Syndrome. Neurol Neuroimmunol Neuroinflamm. 2022; 9(6). PMC: 9562044. DOI: 10.1212/NXI.0000000000200035. View

19.

Reindl M, Waters P . Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nat Rev Neurol. 2018; 15(2):89-102. DOI: 10.1038/s41582-018-0112-x. View

20.

Mayer M, Breithaupt C, Reindl M, Schanda K, Rostasy K, Berger T . Distinction and temporal stability of conformational epitopes on myelin oligodendrocyte glycoprotein recognized by patients with different inflammatory central nervous system diseases. J Immunol. 2013; 191(7):3594-604. DOI: 10.4049/jimmunol.1301296. View